An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.

Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of a significant growth in short interest during the month ...

The global peptide therapeutics market is on a transformative trajectory, expected to surge from USD 42.1 billion in 2024 to an impressive USD 117.4 billion by 2034, registering a robust CAGR of 10.8% ...

Pfizer in 2019 sold $20 billion of drugs in the U.S. Its federal tax bill? Zero. That revelation was part of a Senate Finance ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), ...

Tariffs raise business costs, impacting companies that rely on imported materials. Some firms pass costs to consumers, while ...

And it’s a sentiment I’d like to share today, especially ahead of President Donald Trump’s “Liberation Day” announcements. ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...